Early detection of cancer can dramatically increase the efficacy of curative treatment. Unfortunately, early screening tests exist for only a small number of cancers, meaning most are not diagnosed until symptoms arise in the later stages of the disease.

Better cancer screening is, therefore, a major focus area for clinical performance improvement. Marilyn Sherrill talks with Dr. Joe Cummings about a new genomic test that can theoretically screen for more than 50 different types of cancer using a small blood sample, and what the future may hold for this technology.

Guest speaker:

Moderator:

Show Notes:

[01:28] The Grail Galleri liquid biopsy test.

[02:18] Sampling methodology.

[02:55] The analytic process of the Grail Galleri test, and some developmental history.

[04:01] Testing methodology is based on methylation patterns.

[05:36] Results of the clinical studies to-date, and status of ongoing studies.

[08:13] Early adopters include some larger healthcare systems and, potentially, anyone willing to self-pay.

[09:04] Test costs and preliminary cost/benefit anaylsis.

[11:02] Considerations re: payers’ willingness to cover test costs.

[12:09] Looking forward to trial results and potential FDA approval.

[13:05] With many companies doing R&D in the liquid biospy field, the development of competing and complementary tests is to be expected.

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Google Podcasts

Android

Stitcher

RSS Feed